Consumer watchdog Which? reports that many menopause and perimenopause supplements sold for women cost hundreds of pounds a year but provide no clear benefits over cheap multivitamins.
The outlets describe an investigation suggesting that some products marketed for menopause symptoms are overpriced and do not contain meaningful doses of key nutrients compared with standard over-the-counter options. The findings are presented as a comparison between higher-priced supplements and low-cost multivitamins, with the watchdog concluding that the supplements do not offer additional value.
The coverage is broadly aligned in its central message: supplements positioned as specifically targeted to menopause do not outperform basic formulations. The Daily Mail and Mail Online use stronger language about “marketing hype,” while The Independent and Evening Standard emphasize the results of the Which? investigation and the issue of insufficient nutrient dosing. Across reports, the focus remains on price, ingredient content, and the limited added benefit claimed by manufacturers.
